Paediatric formulations

Developing new products for vulnerable populations


MMV has long recognized that developing better medicines for children helps address the most vulnerable patient population at greatest risk of dying from malaria. MMV and partners are developing and improving access to child-friendly formulations of existing antimalarials for treatment (artemisinin-based combination therapies; ACTs), and chemoprevention (sulfadoxine-pyrimethamine + amodiaquine; SP+AQ), as well as developing next-generation medicines for children in parallel with adult formulations.

Pyramax® granules

Shin Poong

Product category
  • 3-day cure, artemisinin-based combination therapy (pyronaridine-artesunate)

Therapeutic indication


  • Pyramax granules: for the treatment of uncomplicated malaria infection caused by P. falciparum or P. vivax in children and infants weighing 5kg to under 20kg

  • Once-daily for 3 days

  • 28-day PCR-corrected ACPR* >97%

  • 42-day PCR-corrected ACPR* 90%–95%

Key features
  • Only ACT approved by a stringent regulatory authority for both P. falciparum and P. vivax (blood-stage)
  • No food restrictions
  • Child-friendly granules
  • WHO Information Note of October 2019 now supports use, yet not formally included in WHO Malaria Treatment Guidelines

  • Included in WHO Essential Medicines List (adults and children)
  • Included in national treatment guidelines of Côte d’Ivoire, Niger and Republic of Congo
  • Approved in 16 countries, country launches began in 2018 in sub-Saharan Africa
Next milestone
  • National registrations

  • Completion of multi-country phase IIIb/IV CANTAM study for publication

  • Commercial introduction in Africa

  • Development project team led by University of Iowa

MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response 

Subscribe to RSS - Paediatric formulations